Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug combinations
Pharma
BeOne's Venclexta challenger Beqalzi nets FDA approval
MCL is BeOne’s stepping stone to potentially reshape the broader BCL-2 landscape, which is presently dominated by AbbVie and Roche’s Venclexta.
Angus Liu
May 13, 2026 4:45pm
Merck's Welireg surprisingly fails in first-line kidney cancer
Apr 21, 2026 10:00am
Another AstraZeneca Emerald glimmers in liver cancer
Apr 2, 2026 10:12am
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
Mar 19, 2026 6:45am
Merck's Welireg combos deliver 1-2 punch to kidney cancer
Feb 28, 2026 10:00am
Padcev-Keytruda combo wins in MIBC amid evolving landscape
Feb 27, 2026 10:00am
